Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of Genetic Variability on Rifampicin and Isoniazid Pharmacokinetics in South African Patients with Recurrent Tuberculosis

15 Feb 2019

Abstract excerpt

AIM: We report the prevalence and effect of genetic variability on pharmacokinetic parameters of isoniazid and rifampicin. MATERIALS & METHODS: Genotyping OpenArray™. Nonlinear mixed-effects models were used to describe drug pharmacokinetics. RESULTS: Among 172 patients, 18, 43 and 34% were classified as rapid, intermediate and slow NAT2 acetylators, respectively. Of the 58 patients contributing drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood disorders and treatments
Share to Drug-Induced Hepatotoxicity and Protection
Share to Tuberculosis Research and Epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30767706
DOI: 10.2217/pgs-2018-0166

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of Genetic Variability on Rifampicin and Isoniazid Pharmacokinetics in South African Patients with Recurrent TuberculosisPMID 30767706Read ↗

Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models.Semantic proximity Read ↗

Population pharmacokinetics of isoniazid in adult Indian tuberculosis patients: Evaluation of NAT2 polymorphisms.Semantic proximity Read ↗

Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection.Semantic proximity Read ↗

Effect of Genetic Variation of NAT2 on Isoniazid and SLCO1B1 and CES2 on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis.Semantic proximity Read ↗

N-acetyltransferase 2 genotypes amongst Zulu Speaking South Africans and isoniazid / <i>N</i> -acetyl-isoniazid pharmacokinetics during anti-tuberculosis treatmentSemantic proximity Read ↗

N-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and N-Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment.Semantic proximity Read ↗

Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review.Semantic proximity Read ↗

Pharmacogenetic Study of Drugs Affecting Mycobacterium tuberculosis.Semantic proximity Read ↗

Parametric population pharmacokinetics of isoniazid: a systematic review.Semantic proximity Read ↗

Pharmacogenomics and mutation informatics: correlation of NAT2 mutations and isoniazid acetylation rate.Semantic proximity Read ↗

Population pharmacokinetics of isoniazid and dose recommendations in Mexican patients with tuberculosis.Semantic proximity Read ↗

Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.